| Dr James F Knight, MD | |
|
2720 Sunset Blvd, West Columbia, SC 29169-4810 | |
| (803) 791-0000 | |
| Not Available |
| Full Name | Dr James F Knight |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 43 Years |
| Location | 2720 Sunset Blvd, West Columbia, South Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164507182 | NPI | - | NPPES |
| 122708 | Medicaid | SC | |
| 050053901 | Other | SC | RR MEDICARE |
| 122708 | Other | SC | SELECT HEALTH |
| 4287434 | Other | SC | AETNA |
| 2020122 | Other | SC | CCP |
| 77841 | Other | SC | MEDCOST |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lexington Medical Center | West columbia, SC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lexington Health Inc | 2567872070 | 753 |
News Archive
Ocean Nutrition Canada Limited (ONC), the world's largest Omega-3 EPA/DHA solutions provider, and supplier of MEG-3® brand Omega-3 EPA/DHA (eicosapentaenoic acid/docosahexaenoic acid) ingredients, is pleased to announce that it has entered into an exclusive long term strategic agreement with Wilmar International Limited (Wilmar), based in Singapore.
Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.
More than 1 in 10 Americans take antidepressants, but these medications can take weeks-and for some patients, months-before they begin to alleviate symptoms. Now, scientists from the University of Chicago have discovered that selectively blocking a serotonin receptor subtype induces fast-acting antidepressant effects in mice, indicating a potential new class of therapeutics for depression. The work was published Oct. 29 in Molecular Psychiatry.
Kyowa Hakko Kogyo Co. has announced that Kyowa Pharmaceutical, Inc., its wholly owned U.S subsidiary, submitted on April 25, 2007 a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Istradefylline(KW-6002), its investigational drug for Parkinson's disease.
As part of a collaborative initiative, PLOS and the Drugs for Neglected Diseases initiative (DNDi) are delighted to be launching a special Collection-PLOS & DNDi: a decade of Open Access and Neglected Tropical Diseases R&D (Research and Development)-to coincide with a joint event at the Institut Pasteur in Paris celebrating the 10-year anniversary of DNDi.
› Verified 3 days ago
| Entity Name | Lexington Health Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710634753 PECOS PAC ID: 2567872070 Enrollment ID: O20201208000922 |
News Archive
Ocean Nutrition Canada Limited (ONC), the world's largest Omega-3 EPA/DHA solutions provider, and supplier of MEG-3® brand Omega-3 EPA/DHA (eicosapentaenoic acid/docosahexaenoic acid) ingredients, is pleased to announce that it has entered into an exclusive long term strategic agreement with Wilmar International Limited (Wilmar), based in Singapore.
Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.
More than 1 in 10 Americans take antidepressants, but these medications can take weeks-and for some patients, months-before they begin to alleviate symptoms. Now, scientists from the University of Chicago have discovered that selectively blocking a serotonin receptor subtype induces fast-acting antidepressant effects in mice, indicating a potential new class of therapeutics for depression. The work was published Oct. 29 in Molecular Psychiatry.
Kyowa Hakko Kogyo Co. has announced that Kyowa Pharmaceutical, Inc., its wholly owned U.S subsidiary, submitted on April 25, 2007 a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Istradefylline(KW-6002), its investigational drug for Parkinson's disease.
As part of a collaborative initiative, PLOS and the Drugs for Neglected Diseases initiative (DNDi) are delighted to be launching a special Collection-PLOS & DNDi: a decade of Open Access and Neglected Tropical Diseases R&D (Research and Development)-to coincide with a joint event at the Institut Pasteur in Paris celebrating the 10-year anniversary of DNDi.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James F Knight, MD Po Box 6069, West Columbia, SC 29171-6069 Ph: () - | Dr James F Knight, MD 2720 Sunset Blvd, West Columbia, SC 29169-4810 Ph: (803) 791-0000 |
News Archive
Ocean Nutrition Canada Limited (ONC), the world's largest Omega-3 EPA/DHA solutions provider, and supplier of MEG-3® brand Omega-3 EPA/DHA (eicosapentaenoic acid/docosahexaenoic acid) ingredients, is pleased to announce that it has entered into an exclusive long term strategic agreement with Wilmar International Limited (Wilmar), based in Singapore.
Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.
More than 1 in 10 Americans take antidepressants, but these medications can take weeks-and for some patients, months-before they begin to alleviate symptoms. Now, scientists from the University of Chicago have discovered that selectively blocking a serotonin receptor subtype induces fast-acting antidepressant effects in mice, indicating a potential new class of therapeutics for depression. The work was published Oct. 29 in Molecular Psychiatry.
Kyowa Hakko Kogyo Co. has announced that Kyowa Pharmaceutical, Inc., its wholly owned U.S subsidiary, submitted on April 25, 2007 a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Istradefylline(KW-6002), its investigational drug for Parkinson's disease.
As part of a collaborative initiative, PLOS and the Drugs for Neglected Diseases initiative (DNDi) are delighted to be launching a special Collection-PLOS & DNDi: a decade of Open Access and Neglected Tropical Diseases R&D (Research and Development)-to coincide with a joint event at the Institut Pasteur in Paris celebrating the 10-year anniversary of DNDi.
› Verified 3 days ago
Dr. Jonathan Cates, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-936-7372 Fax: 803-936-4102 | |
Andrew S. Weisinger, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 | |
Dr. Charles E Corley, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-254-2394 Fax: 803-254-7125 | |
Dr. Charles T Campbell, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 | |
Jialiu David Li, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 222 E Medical Ln Ste 100&200, West Columbia, SC 29169 Phone: 803-935-8410 Fax: 803-936-7816 | |
Dr. Patrick S. Sipe, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2720 Sunset Blvd, West Columbia, SC 29169 Phone: 803-791-2000 |